Several banks rate LLY Overweight or Outperform with targets around $1,400. Lilly reports EloraTZP produced up to 23.3% average weight loss over 48 weeks in Phase 2b.
Recap by typeshit. Full story at timothysykes.
Kalkine Media ties the attention on Lilly to orforglipron's progress, arguing a pill could scale cheaper than injectables and ease supply limits.
Smaller portions could become more common on shelves, with inflation and GLP-1 appetite changes both pushing food makers toward personal packs.
Chokshi notes the sales were 0.4% of Lilly's $23 billion quarter, and that Divi's Labs hasn't announced any role in making the drug.
Oral Wegovy brought in about $850 million in H1 2026 and holds over 80% of new US oral scripts. Lilly says Foundayo volume doubled in a month.
The eye clinic says most people on GLP-1 medicines don't need extra eye checks, but advises staying alert to any shift in eyesight.
A primer on Eli Lilly's investigational weight-loss shot, its trial results and the possible timeline for approval and availability.
Loading…